Stockwinners Market Radar for May 19, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:16 EDT Overstock.com director Corbus sells 6,720 common shares - In a regulatory filing, Overstock.com director Barclay Corbus disclosed the sale of 6,720 common shares of the company on May 18 at a price of $77.51 per share.

18:47 EDT Clovis to present data of Rubraca and Lucitanib trials at ASCO - Clovis announced that four abstracts featuring data from clinical studies evaluating Rubraca and/or lucitanib and one abstract on real world data of PARP inhibitor usage, will be presented during the 2021 American Society of Clinical Oncology Annual Meeting to be held virtually, June 4-8, 2021. New data "analyses from the Phase 3 ARIEL3 and ARIEL4 trials further characterize Rubraca's efficacy and consistent safety profile in patients in the advanced ovarian cancer maintenance treatment and treatment settings", the company states.

18:44 EDT NextCure to present NC410 study data at ASCO - NextCure announced that clinical trial investigator, Martin Gutierrez, M.D., Director, Phase 1 Program and Co-Chair of Thoracic Oncology at Hackensack University Medical Center, will present a Trials in Progress poster for NC410 at the 2021 American Society of Clinical Oncology Annual Meeting. "We are excited to discuss our rationale for developing NC410 as a first-in-class cancer therapeutic targeting the LAIR pathway as well as our Phase 1/2 clinical trial strategy with the clinical oncology community at ASCO," said Han Myint, M.D., NextCure's chief medical officer. "NC410 demonstrates anti-tumor activity in preclinical models, and we believe it has significant potential across multiple tumor types, including gastric, ovarian, lung head and neck. We look forward to continuing to evaluate NC410 in first-in-human trials and reporting initial clinical data in the second half of 2021."

18:32 EDT Take-Two CEO: We expect to set new records - In an interview on CNBC's Mad Money, Strauss Zelnick said Take-Two has 21 titles coming to market this year. The company is highly efficient, he noted. This is still "early days" for e-sports, he added. Golf is going to be "huge for us," he said and the company is investing heavily in it.

18:08 EDT I-MAB presents Phase 1 data on CD73 antibody uliledlimab - I-Mab announced that an abstract detailing clinical data from its U.S. phase 1 study of uliledlimab in combination with atezolizumab in patients with advanced cancer will be presented at the 2021 American Society of Clinical Oncology Annual Meeting, taking place June 4-8. Uliledlimab is a humanized CD73 antibody and is designed to counter the adenosine-mediated immunosuppressive tumor microenvironment, rendering anti-tumor immune cells to act more effectively in response to checkpoint immunotherapies. Preclinical studies have shown that when combined with a PD-(L)1 antibody, uliledlimab exhibited a superior and synergistic inhibitory effect on tumor growth versus PD-(L)1 mono-therapy. The U.S. phase 1 dose escalation study of uliledlimab in combination with atezolizumab showed that the treatment is safe and well tolerated with no dose-limiting toxicity. All treatment related adverse events were either grade 1 or grade 2. Uliledlimab demonstrated a linear pharmacokinetic profile and reached full receptor occupancy on B cells at the middle and high dose levels. Tumor types of patients who had complete or partial responses or stable disease included ovarian clear cell carcinoma, non-small cell lung cancer and a few other cancers. I-Mab has made significant progress in clinical trials in China to evaluate uliledlimab in combination with toripalimab in patients with advanced or metastatic cancers, including non-small cell lung cancer, who are refractory to or intolerant of available therapies.

18:02 EDT Myriad Genetics to share results for breast cancer risk assessment study at ASCO - Myriad Genetics "announced that it will present results from a study with more than 275,000 women validating the use of a new method for polygenic breast cancer risk assessments in women of all ancestries. The new data will be shared in an oral presentation with leading collaborators on June 4 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Myriad Genetics plans to launch riskScore for all ancestries later this year as part of its myRisk clinical test. In addition, the company recently announced plans to launch a standalone consumer version of riskScore in 2022. The consumer version will further expand riskScore access to a new population of 93 million women who do not already qualify for hereditary cancer testing due to their personal or family history."

17:59 EDT Guardant Health to present LUNAR-2 blood test for cancer detection at ASCO - Guardant Health will present data "demonstrating the use of the company's proprietary blood tests to advance precision oncology, including cancer screening, detecting residual or recurrent disease in early-stage cancer, and treatment selection and treatment response monitoring in advanced cancer. Data, from 20 abstracts, will be presented along with other leading medical institutions and pharmaceutical companies, during the 2021 American Society of Clinical Oncology Annual Meeting being held from June 4-8, 2021. The data show that the LUNAR-2 assay achieved overall sensitivity of 91% in early-stage CRC and specificity of 94%. The performance in this new large cohort of CRC cases, and cancer-free controls, is consistent with previously reported data.1-2 Notably no differences in sensitivity for CRC detection were observed in patients presenting with asymptomatic disease, compared to those patients who were symptomatic, despite the lower cell-free DNA tumor fractions observed in asymptomatic patients, suggesting the test will have clinically meaningful performance in an average-risk screening population".

17:54 EDT FDA clears thawed Pfizer, BioNTech COVID vaccine to be stored for up to 1 month - Based on a review of recent data submitted by Pfizer (PFE), the U.S. FDA is authorizing undiluted, thawed Pfizer-BioNTech (BNTX) COVID-19 vaccine vials to be stored in the refrigerator at 2 degrees C to 8 degrees C (35 degrees F to 46 degrees F) for up to 1 month. Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to 5 days. Reference Link

17:24 EDT Nacco Industries increases regular cash dividend to 19.75c per share - Nacco Industries increased its regular cash dividend from 19.25c to 19.75c per share. The dividend is payable on both the Class A and Class B Common Stock, and will be paid June 15 to stockholders of record at the close of business on June 1.

17:20 EDT Sutro Biopharma to present ph1 study data of STRO-002 at ASCO - Sutro Biopharma "announced additional data from the company's dose-escalation cohort of the Phase 1 study of STRO-002, a folate receptor alpha targeting antibody-drug conjugate for patients with advanced, progressive ovarian cancer; the data will also be presented as a poster at the American Society of Clinical Oncology 2021 Annual Meeting to be held on June 4-8, 2021. Of the 31 patients evaluable for RECIST, 10 patients met criteria for response. One patient achieved a complete response and nine patients achieved a partial response. Of the nine PRs, four were confirmed PRs and five were unconfirmed PRs".

17:17 EDT Blueprint Medicines to present ARROW trial data demonstrating GAVRETO benefits - The company states: "Blueprint Medicines announced the presentation of updated Phase 1/2 ARROW trial data demonstrating durable clinical benefits of GAVRETO in metastatic RET fusion-positive non-small cell lung cancer and other advanced solid tumors. GAVRETO showed high response rates in treatment-naive patients with RET fusion-positive NSCLC, clinical activity across a number of RET fusion-positive tumor types and a safety profile consistent with previously reported results. These data will be presented during the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8."

17:11 EDT Amgen to showcase new data from oncology portfolio at ASCO - The company states: "Amgen announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 2021 American Society of Clinical Oncology Annual Meeting taking place virtually from June 4-8, 2021. Overall survival data from the Phase 2 CodeBreaK 100 trial of LUMAKRAS, a potentially first-in-class KRASG12C inhibitor in non-small cell lung cancer will be presented for the first time alongside additional exploratory biomarker subgroup analyses in an oral presentation on Friday, June 4, 2021. Updated data for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial will also be shared in an oral presentation on Friday, June 4, 2021, in patients with FGFR2b+ advanced gastric and gastroesophageal junction adenocarcinoma."

17:09 EDT Advaxis announces update from ADXS-503 study - Advaxis announced updated data from the company's ongoing Phase 1/2 study evaluating ADXS-503 in combination with Keytruda which will be presented as a poster at the American Society of Clinical Oncology, or ASCO. ADXS-503 is the first drug construct from the ADXS-HOT off-the-shelf, cancer-type specific, immunotherapy program which leverages Advaxis' proprietary Lm technology platform to target hotspot mutations that commonly occur in specific cancer types as well as other proprietary, tumor-associated antigens. Ten patients have been treated with ADXS-503 as an add on therapy to patients failing pembrolizumab as last therapy with 10 patients evaluable for safety and nine patients evaluable for efficacy. Combination therapy was well tolerated with no DLTS or added toxicity of the two drugs. Grade 1 and 2, transient and reversible events included chills, fever, fatigue, in approximately half of the patients. The disease control rate was 44%. Clinical benefit was durable, with an observed partial response, or PR, and stable disease (SD) sustained for over a year, and another observed SD lasting over six months. An additional PR was maintained for approximately four months. Biomarker data demonstrate that patients who seem to achieve clinical benefit include those with PD-L1 expression =50%, secondary resistance disease to pembrolizumab and those who show proliferation and/or activation of NK and CD8+ T cells within the first weeks of therapy. Translational studies show: Antitumoral T-cell responses elicited against hot-spot mutation antigens and/or tumor associated antigens. Emergence of naive CD8+ Tcell clones, suggesting reactivity against novel antigens. Induction of proliferation and/or activation of pre-existing CD8+ T-cell clones, including PD-1 upregulation. Enrollment in Part B of the ongoing study will continue to further evaluate the clinical benefit and immune effects of adding on ADXS-503 to patients progressing on pembrolizumab. The Phase 1/2 clinical trial of ADXS-503 is seeking to establish the recommended dose, safety, tolerability and clinical activity of ADXS-503 administered alone and in combination with a Keytruda in approximately 50 patients with NSCLC, in at least five sites across the U.S. The two dose levels with monotherapy in Part A have been completed. Part B with ADXS-503 in combination with Keytruda is currently enrolling its efficacy expansion for up to 18 patients at dose level 1 with the potential to proceed to dose level 2 at a later date. Part C, which is evaluating ADXS-503 in combination with Keytruda as a first line treatment for patients with NSCLC with PD-L1 expression is 1% or who are unfit for chemotherapy is currently enrolling patients.

17:08 EDT Veracyte announces pivotal clinical validation data for nasal swab test - Veracyte announced pivotal clinical validation data showing that the company's noninvasive nasal swab test can significantly improve the early assessment of lung cancer. The new findings show that the Percepta Nasal Swab, a first-of-its-kind genomic test, accurately classifies lung cancer risk in current or former smokers with lung nodules so that those with benign nodules may safely avoid unnecessary additional procedures, while those with likely cancerous nodules may receive more timely diagnosis and treatment. The findings will be presented June 4 at the American Society of Clinical Oncology, ASCO, Annual Meeting. "Lung nodules are often the first sign of lung cancer and cannot be ignored, yet most of them are benign," said Carla R. Lamb, M.D., interventional pulmonologist at Lahey Hospital & Medical Center in Burlington, Mass., who was an investigator on the nasal classifier study. "Today, physicians have limited objective tools to determine which patients with lung nodules found on CT scans have cancer and which don't. Our findings showed that the nasal swab test can determine, with a high level of accuracy, which patients are at low risk of cancer and can avoid invasive procedures. Similarly, it can identify which patients are at high risk and may be confidently directed to further work-up and, potentially, to the treatment they need. An objective tool that can accurately inform these decisions could be a game-changer for early lung cancer assessment."

17:06 EDT Arcus presents early data from ARC-6 Phase 1b/2 study - Arcus Biosciences announced initial efficacy and safety data from one of the cohorts in ARC-6, a randomized Phase 1b/2 platform study, evaluating the novel combination of etrumadenant plus zimberelimab and docetaxel in people with taxane-naive mCRPC who progressed following treatment with one or more new hormonal agents and were checkpoint inhibitor-naive. In this Phase 1b cohort of the etrumadenant-based combination, a composite ORR of 41% and a PSA response of 35% were observed. The safety profile was consistent with the known profiles of each individual agent, and no significant additive toxicity was observed with the addition of etrumadenant. These data will be presented in a poster session at the American Society of Clinical Oncology Annual Meeting taking place June 4-8. "We are encouraged by these early data that indicate the etrumadenant-based combination is well tolerated and demonstrates promising clinical activity in people with advanced disease who progressed on prior treatments," said Bill Grossman, M.D., Ph.D., Chief Medical Officer of Arcus. "Based on these data, we have initiated enrollment into the randomized Phase 2 portion of this arm in the ARC-6 platform study, which compares the etrumadenant-based regimen to standard of care." "Prostate tumors produce high levels of adenosine, which is believed to be immunosuppressive," said Sumit K. Subudhi, M.D., Ph.D., Department of Genitourinary Medical Oncology, Division of Cancer Medicine at the University of Texas, M.D. Anderson Cancer Center. "I am encouraged by the early evidence of clinical response and composite ORR of 41% observed in this study cohort, indicating adenosine receptor blockade with an etrumadenant-based combination may have a role in the treatment of prostate cancer."

17:05 EDT Aveo Pharmaceuticals jumps over 6% to $7.30 after tivozanib phase 3 update

17:05 EDT Adaptimmune reports initial data from Phase 2 SPEARHEAD-1 trial - Adaptimmune Therapeutics will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel at ASCO. "Patients are seeing substantial benefit from afami-cel in SPEARHEAD-1 across a broad range of cell doses and levels of MAGE-A4 expression," said Adrian Rawcliffe, Adaptimmune CEO. "We have shown a high response rate and these responses are still evolving in many patients with increasing depths of response over time and encouraging durability. I am confident that SPEARHEAD-1 will support our BLA submission next year and offer a life-changing treatment for people with synovial sarcoma."

17:04 EDT Sensei Biotherapeutics announces new clinical data from combo trial of SNS-301 - Sensei Biotherapeutics announced new data from the ongoing Phase 1/2 clinical trial of SNS-301, an investigational medicine in patients with advanced squamous cell carcinoma of the head and neck, in combination with pembrolizumab. The data will be presented as a poster by Alain Algazi, M.D., from the University of California San Francisco to the medical community at the 2021 American Society of Clinical Oncology Annual Meeting, taking place virtually June 4 - 8, 2021. As of the April 14, 2021 cut-off date, 21 patients with locally advanced unresectable or metastatic SCCHN had been enrolled and treated in the study. Twenty of the patients enrolled did not achieve an objective response to prior treatment with PD-1 blockade and one patient was PD-1 blockade naive. The safety profile of SNS-301 in combination with pembrolizumab observed from 20 evaluable patients was favorable and consistent with previously reported data. Efficacy data was available from twelve patients in Cohort A. Notably, the efficacy bar was set high by enrolling patients with no objective response to prior PD-1 blockade. Data from nine evaluable patients from Cohort A were last reported from this study at the Society for Immunotherapy of Cancer's 35th Annual Meeting. "These data suggest SNS-301, when combined with PD-1 blockade, has the potential to provide long-term benefit as second and later line treatment for patients with late-stage cancer and few other treatment options," said Marie-Louise Fjallskog, M.D., Ph.D., Chief Medical Officer of Sensei Biotherapeutics. "We expect to report more mature data, including data for SNS-301 combination therapy in the frontline setting, by the end of this year."

17:02 EDT Black Diamond Therapeutics presents Phase 1 data for BDTX-189 - Black Diamond Therapeutics announced initial data from the Phase 1 dose-escalation portion of the MasterKey-01 trial of BDTX-189 in patients with advanced solid tumors harboring any one of more than 48 oncogenic alterations in the epidermal growth factor receptor, EGFR, and human epidermal growth factor receptor 2, HER2, oncogenes. These data provide early proof-of-concept for BDTX-189, including evidence of anti-cancer activity and a safety profile that is in-line with the company's preclinical expectations. The data announced will be presented in poster presentations at the upcoming 2021 ASCO Annual Meeting, taking place June 4-8. "These encouraging Phase 1 safety and anti-cancer activity data provide early proof-of-concept for BDTX-189 as a differentiated MasterKey inhibitor of undrugged oncogenic mutants of EGFR, including EGFR Exon 20 insertion mutations and oncogenic mutants of HER2," said Rachel Humphrey, M.D., Chief Medical Officer of Black Diamond Therapeutics. "We look forward to the continued advancement of BDTX-189 through clinical development and remain on track to initiate the potentially pivotal Phase 2 portion of the MasterKey-01 trial in the second half of 2021."

17:01 EDT Euronet enters joint venture with Prosegur Cash - Euronet Worldwide (EEFT) and Prosegur Cash (PGUCY) announces an "alliance between both parties through the establishment of a joint venture to provide comprehensive ATM outsourcing services and to own and deploy independent ATMs in the majority of the countries of Latin America. The implementation of the alliance in the different countries is subject, among others, to obtaining the relevant authorizations from regulators, including, in particular, relevant antitrust authorizations. The joint venture will leverage Euronet's REN and REV payments technologies such as its cloud-based processing and connections to domestic switches and bank hosts for authorizations."

16:49 EDT Hamilton Beach raises quarterly dividend 5% to 10c from 9.5c per share - The dividend is payable on both the Class A and Class B Common Stock and will be paid June 15 to stockholders of record at the close of business on June 1.

16:42 EDT Domino's Pizza CFO that Stuart Levy to step down - Domino's Pizza announced that Stuart Levy will be leaving the company to pursue other opportunities. While he is stepping down from his role as Executive Vice President and CFO effective immediately, Levy will continue with the company in an advisory capacity until August 31 to ensure a smooth transition. The company has commenced a search for the next CFO with the assistance of Heidrick & Struggles. Effective immediately, Ritch Allison, Domino's CEO, will assume oversight of a newly established Office of the CFO comprised of Ryan Goers, Vice President, Finance, Global Financial Planning and Analysis; Juan Jose Joachin, Vice President, Finance Operations; and Jessica L. Parrish Vice President, Corporate Controller and Treasurer until the new CFO is in place. Levy's departure did not result from any disagreement regarding the company's financial reporting or accounting policies, procedures, estimates, or judgments.

16:35 EDT Nuvve Holding, Spirii announce agreement to deploy VGI technology in Denmark - Nuvve Holding and Spirii have agreed to deploy vehicle-grid integration, or VGI, technology in Denmark, the Nordics, and Northern Europe. The agreement will allow integration of both company's platforms to provide V1G grid services and V2G customer offers for electric vehicle, or EV, fleets. VGI encompasses both V1G and V2G charging to offer a range of opportunities made possible by Nuvve's GIVe V2G cloud-based software platform to meet various customer needs. The Nuvve operations in Denmark have been a pioneering center for V2G operations in Europe with multiple EV fleets. Over the last four years, Nuvve has provided frequency regulation for Energinet, the Danish grid system operator, based on the Nuvve GIVe V2G software platform which complements the high percentage of offshore wind generation. Other services such as smart charging services and tariff management ensure that V2G always provides fleets with the lowest operational costs. Nuvve has established strong local relationships in the region with Technical University of Denmark and others from participation in local projects like Nikola, Parker, and ACES which demonstrated the capabilities and advantages of bidirectional V2G charging since 2013.

16:31 EDT Wunong Net Technology discloses Nasdaq notice of listing non-compliance - Wunong Net Technology announced that it "received written notification on May 18, 2021, from The Nasdaq Stock Market LLC that it no longer complies with Listing Rule 5250(c)(1) for continued listing in that it has failed to file its annual report on Form 20-F for the year ended December 31, 2020. Under the Nasdaq Rules, the company has 60 calendar days to submit a plan to regain compliance. If its plan is accepted, the company will be granted an extension of up to 180 calendar days from the filing's due date to regain compliance."

16:30 EDT CoreSite Realty raises quarterly dividend to $1.27 from $1.23 per share - The dividend will be paid on July 15 to shareholders of record as of June 30.

16:23 EDT Kearny Financial boosts dividend to 10c per share - Kearny Financial announced that the Company's Board of Directors has declared a quarterly cash dividend of 10c per share. This represents an increase of 1c from the prior quarter's dividend of 9c per share.

16:22 EDT Central Securities announces Wilmot Kidd to step down as CEO - At a board meeting today, Wilmot H. Kidd announced that he will step down as CEO of Central Securities as of December 31, 2021. He will continue to serve the Corporation as Chairman of the Board of Directors. Today, in addition to his position as President, Mr. John C. Hill was unanimously elected to succeed Mr. Kidd as Chief Executive Officer effective January 1, 2022. Mr. Hill was also elected to the Corporation's Board of Directors effective today.

16:19 EDT Silicon Labs to buy back up to $150M in common stock - The board of Silicon Laboratories authorized a new program to repurchase up to $150M of Silicon Laboratories common stock through December 2021.

16:12 EDT NuVasive appoints Daniel Wolterman as independent board chair - NuVasive appointed Daniel Wolterman as independent chair of the NuVasive Board of Directors, effective immediately. Wolterman succeeds Gregory Lucier as the company's Board chair, following Lucier's retirement from the Board on May 18. Wolterman joined the company's Board in July 2015 and served as the Board's lead independent director since May 2020. The NuVasive Board of Directors is now comprised of nine directors and includes a group of current and former executives in the healthcare, medical device, and technology sectors. The company will no longer designate a lead independent director of its Board.

16:11 EDT Y-mAbs in pact with Adium for DANYELZA, Omburtamab Latin American distribution - Y-mAbs Therapeutics announced that it has entered into an exclusive distribution agreement with Adium Pharma S.A. to be the exclusive distributor in Latin America of the Company's antibodies, DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. DANYELZA or naxitamab-gqgk, 40mg/10mL was approved by the U.S. Food and Drug Administration on November 25 and is indicated, in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. The distribution agreement includes the territories of Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay, and certain Caribbean islands. Under the terms of the agreement, Adium will employ its sales and marketing expertise to distribute DANYELZA and omburtamab, if approved, in the territory. In addition, Adium will submit registration files on behalf of the Company in certain parts of the territory. All other unpartnered geographies worldwide remain with the Company. Financial details were not disclosed."We are very pleased to enter this distribution agreement with Adium, a company with a commercial presence in 18 countries and a sustained oncology and rare disease business. We hope to leverage Adium's footprint in Latin America to make DANYELZA and omburtamab, if approved, available to children with unmet medical needs," said Thomas Gad, founder, Chairman and President at Y-mAbs.

16:09 EDT Cisco reports Q3 adjusted gross margin 66% - On a non-GAAP basis, total gross margin, product gross margin, and service gross margin were 66.0%, 64.9%, and 68.7%, respectively, as compared with 66.6%, 65.8%, and 68.9%, respectively, in the third quarter of fiscal 2020. Total gross margins by geographic segment were: 66.5% for the Americas, 65.6% for EMEA and 64.7% for APJC.

16:07 EDT Cisco CEO says 'great quarter with strong demand across the business' - "Cisco had a great quarter with strong demand across the business," said Chuck Robbins, chairman and CEO of Cisco. "We are confident in our strategy and our ability to lead the next phase of the recovery as our customers accelerate their adoption of hybrid work, digital transformation, cloud, and continued strong uptake of our subscription-based offerings." "We executed well with strong product orders, and solid growth in revenue, net income, and EPS," said Scott Herren, CFO of Cisco. "Our investments in innovation and accelerated shift to more software offerings and subscriptions led to double-digit growth in deferred revenue, remaining performance obligations and higher levels of recurring revenue."

16:05 EDT Voyager Therapeutics CEO Andre Turenne, CMO Omar Khwaja step down - Voyager Therapeutics announced leadership transitions and a strategic shift toward a refocused pipeline and expanded investment in its AAV capsid platform, TRACER. The company expects its TRACER technology platform to enable development of novel gene therapy candidates for serious neurological diseases that have been challenging to address with conventional approaches. Michael Higgins, chairman of the board of directors, will assume the role of interim CEO and Glenn Pierce, board director, will assume the role of interim chief scientific officer, or CSO. Higgins succeeds Andre Turenne, who has decided to step down from his roles as president and CEO and as a board director, effective in early June, to pursue new opportunities. Turenne will support the company in an advisory capacity as the company searches for a permanent CEO. Voyager also announced that Omar Khwaja has resigned from his role as chief medical officer, or CMO, and head of research and development, effective at the end of May. Khwaja will be returning to Europe to pursue a new scientific and clinical leadership opportunity. Higgins has served on Voyager's board of directors since July 2015 and has been chair of the board since June 2019. Pierce has been a member of the board of directors since January 2017. The company's board has commenced a search process to identify a permanent chief executive officer and chief scientific officer.

15:32 EDT Cumberland names John Hamm as new CFO - Cumberland Pharmaceuticals announced that it has promoted John Hamm to Director Finance & Accounting and CFO. In this role, he will manage all of Cumberland's finance and accounting activities while continuing to oversee corporate development and legal matters. Hamm has more than 25 years of finance and accounting experience, including 20 years in health care. He previously served as Cumberland's Director Corporate Development, where he was responsible for business development, alliance management and legal activities. Prior to joining Cumberland in 2019, Hamm served in senior executive positions in the health care, broadcasting and telecom industries. Hamm is the former COO at HealthSpring and CFO for their pharmacy business.

14:49 EDT Google Maps expands features including new Live View 'busyness' of area - Director of Product, Google Maps Oren Naim wrote earlier, in part: "Today at Google I/O, we're announcing five new updates so you can more easily navigate, explore and get things done. Reduce hard-braking with routing updates... Google Maps will reduce your chances of having hard-braking moments along your drive thanks to help from machine learning and navigation information...Walk this way with enhancements to Live View and detailed street maps.Walk this way with enhancements to Live View and detailed street maps If you're getting around on foot, we've got you covered with augmented reality in Live View. If you're exploring a new neighborhood, you'll be able to access Live View instantly - right from the map...Spot busy areas at a glance.. Google for specific places is expanding ...to show the relative busyness of an entire area, like whether a neighborhood or part of town is busier than usual. If it's Saturday morning and you want to explore your city without crowds bogging you down, open up Maps to instantly see busy hotspots to avoid." Reference Link

14:30 EDT Lennox raises quarterly dividend 19% to 92c per share - The board of directors of Lennox International Inc. voted to increase the quarterly cash dividend 19% to 92c per share of common stock. The dividend is payable on July 15, 2021, to stockholders of record as of June 30, 2021.

13:49 EDT North American rail traffic rose 25.6% in week ended May 15, AAR says - The Association of American RailroadS, AAR, reported U.S. rail traffic for the week ending May 15. For this week, total U.S. weekly rail traffic was 533,872 carloads and intermodal units, up 28.3% compared with the same week last year.Total carloads for the week ending May 15 were 242,806 carloads, up 31.6% compared with the same week in 2020, while U.S. weekly intermodal volume was 291,066 containers and trailers, up 25.6% compared to 2020. North American rail volume for the week ending May 15, on 12 reporting U.S., Canadian and Mexican railroads totaled 341,527 carloads, up 29% compared with the same week last year, and 384,770 intermodal units, up 22.7% compared with last year. Total combined weekly rail traffic in North America was 726,297 carloads and intermodal units, up 25.6% . North American rail volume for the first 19 weeks of 2021 was 13,290,858 carloads and intermodal units, up 10.9% compared with 2020. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Genesee & Wyoming (GWR), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP). Reference Link

13:39 EDT Treace Medical announces interim results from ALIGN3D study - Treace Medical Concepts announced interim results from the ALIGN3D clinical study in a podium presentation at the ongoing American College of Foot and Ankle Surgeons, or ACFAS, Annual Scientific Conference. Data on the 128 study participants included in the interim analysis demonstrated: Early return to weightbearing in a walking boot at an average of 8.3 days; Significant improvements in radiographic measurements of 3-dimensional bunion correction; 1.4% recurrence rate observed, or 1 out of 72 patients, at 12 months post-surgery; and significant improvements in patient-reported pain reduction and quality of life measurements at 6 months, which were maintained at 12 months post procedure. John Treace, CEO of Treace commented, "The Lapiplasty 3D Bunion Correction system was developed to provide surgeons the tools and surgical methods to reliably correct all 3 dimensions of the bunion deformity and address its root cause. ALIGN3D is a unique and comprehensive 5-year study, and we are pleased to report these positive interim results. We look forward to continuing to build our robust portfolio of clinical evidence, as we advance the standard of care for bunion surgery with our proprietary Lapiplasty procedure."

13:25 EDT Engine No. 1 issues message to Exxon Mobil shareholders - Engine No. 1, which has nominated four independent director candidates to the Exxon Mobil Corporation Board of Directors, issued a message to ExxonMobil shareholders. The message says in part: "Shareholders have a pivotal decision to make about the future of Exxon Mobil Corporation at next week's annual meeting of shareholders, and we want to make sure that every shareholder has the facts necessary to cast a fully informed vote. We therefore wish to address some important topics in the closing days of this effort, and we encourage shareholders to contact us with any additional questions or concerns if we can be helpful. ExxonMobil has unfortunately attributed a number of quotes or suggestions to us that we never made... In our first letter to the Company on December 7, 2020 listing the qualifications of our nominees, we said that, "We are open to engaging in a constructive dialogue to discuss these individuals before the need arises to nominate them for election to the Board." This was almost two months before the date such nominations were due. In January an advisor to the Company informed us that the Board would not appoint or even meet with any of our nominees but offered to let us sign a confidentiality agreement to learn what the Company planned to announce and get some credit for it. When we asked the Company's CEO and Lead Board Director in our only meeting with them why they would refuse to even meet our nominees, we were told that the Board generally looks for former CEOs of public companies (but still refused to meet with even the 2 who met this criteria). Thereafter, the Board expanded itself after the date such nominations were due, adding 3 people who have not served as public company CEO's. We do not believe this constitutes constructive engagement, nor does gaining the support of one shareholder for adding directors with no energy experience with no shareholder vote in an effort to fight off more meaningful change. None of our nominees have ever been contacted by or spoken to ExxonMobil about potentially joining its Board, before or after we nominated them. We have also been informed that a new member of the Board has privately claimed that we asked him to join our slate; this is also false, as we limited our search to nominees with energy experience."

13:11 EDT Century Communities trading resumes

13:06 EDT EU General Court upholds Ryanair action for annulment of TAP decision - The General Court of the European Union has upheld an action brought by the airline Ryanair for annulment of a decision related to Portuguese airline TAP, while suspending the effects of the annulment pending the adoption of a new decision by the Commission. In its judgment, the General Court clarifies the scope of the Commission's duty to state reasons where, pursuant to the Guidelines on aid to undertakings in difficulty, it declares aid granted to a company belonging to a group to be compatible with the internal market under Article 107(3)(c) TFEU. In June 2020, Portugal notified the Commission of State aid for the airline Transportes Aereos Portugueses SGPS SA, the parent company and 100% shareholder in TAP Air Portugal. The notified aid, the maximum budget of which is EUR1.2B, concerns a loan agreement concluded between, in particular, Portugal as lender, TAP Air Portugal as borrower and the beneficiary as guarantor. By that measure, Portugal intended to keep the beneficiary in operation for six months, between July 2020 and December 2020. Finding that the notified scheme constituted State aid within the meaning of Article 107(1) TFEU, the Commission appraised it by reference to Article 107(3)(c) TFEU and its Guidelines on State aid for rescuing and restructuring non-financial undertakings in difficulty. By decision of 10 June 2020, the Commission declared the measure at issue to be compatible with the internal market. Reference Link

13:00 EDT Wells Fargo says cryptocurrencies have evolved into 'viable investment asset' - In a report, Wells Fargo's Investment Institute said that it believes cryptocurrencies have evolved into a viable investment assets, and believes long-term supply and demand trends support further industry growth, the potential for further compression in price volatility, and a possible role as portfolio diversifiers. The firm views digital assets as an alternative investment for qualified investors through a professionally managed fund, though due to the uniqueness, complexity and continued evolution of these assets, it plans to produce a series of reports with a goal of increasing investor education and understanding of cryptocurrencies. Several crucial events in 2020 drew increased mainstream usage in transactions and accelerated the maturation of cryptocurrency markets. First, banks received regulatory permission to custody cryptocurrencies, and the investment industry and regulators took additional steps to extend a legal and oversight framework that should help solidify cryptocurrencies as investable assets. The coronavirus pandemic also played a role by fast-tracking the digital economy, as the return to near-zero interest rates sparked inflation fears and interest in alternative payment systems, according to Wells Fargo. "Cryptocurrencies have gained stability and viability as assets, but the risks lead us to favor investment exposure only for qualified investors, and even then through professionally managed funds," Wells Fargo Investment Institute said. "Such a private placement could serve alongside private equity and debt strategies as the primary means of capturing long-term trends from the emergence of next-era digital technologies and infrastructure. Currently, we offer only private placements, because the Securities and Exchange Commission (SEC) has not yet approved an exchange-traded fund (ETF), although increasing numbers of U.S. financial firms are seeking approval. If, or when, more liquid professionally managed vehicles become available, we will consider them at that time. We expect more availability as the industry and investors come to understand better the trends toward digitization in economic activity and the demand for cryptocurrencies and blockchain technologies." Reference Link

12:48 EDT Century Communities initiates quarterly dividend of 15c per share - Century Communities announced that its Board of Directors has approved the initiation of a quarterly cash dividend. The first dividend of 15c per share, or 60c per share on an annualized basis, will be paid on June 16, 2021 to stockholders of record as of the close of business on June 2, 2021. Dale Francescon, Chairman and Co-CEO, stated, "Since becoming a public company seven years ago, we have focused on growing our business and creating long term value for our shareholders. We are pleased with the Board's decision to initiate a quarterly dividend, which reflects our achievements in becoming a larger and more profitable company, strengthening our balance sheet and generating sustainable free cash flows."

12:23 EDT AMD board approves $4B share repurchase program - AMD announced that its Board of Directors approved a new share repurchase program. Under this program, the company intends to repurchase up to $4B of outstanding AMD common stock. AMD expects to fund repurchases through cash generated from operations which have been strengthened by the company's strong operational results. Under this program, the company will repurchase stock in the open market. This repurchase program has no termination date and may be suspended or discontinued at any time.

12:00 EDT AMC Entertainment falls -11.2% - AMC Entertainment is down -11.2%, or -$1.57 to $12.46.

12:00 EDT BIT Mining Limited falls -18.4% - BIT Mining Limited is down -18.4%, or -$2.52 to $11.18.

12:00 EDT Gamco Investors rises 8.8% - Gamco Investors is up 8.8%, or $2.34 to $28.96.

12:00 EDT Iovance Biotherapeutics extends decline to 33% after CEO resigns - Shares of Iovance Biotherapeutics, which were already lower after the company discussed its receipt of feedback from the FDA on potency assays and pushed out guidance for a BLA filing on tumor infiltrating lymphocyte therapy lifileucel to the first half of 2022, have slid further following the disclosure that President and CEO Maria Fardis notified the company that she will be resigning to pursue other opportunities. Near noon, Iovance shares are now down $8.84, or 33%, to $18.13.

11:58 EDT Iovance Biotherapeutics trading halted, volatility trading pause

11:57 EDT Epic Games, NBA collaborate to bring NBA content to 'Fortnite' - Epic Games' "Fortnite" is collaborating with the NBA ahead of the 2021 NBA playoffs. Coinciding with the debut of the State Farm NBA Play-In Tournament, "Fortnite x NBA: The Crossover" brings basketball's best into the Item Shop and Fortnite Creative, and with Team Battles, a unique experience featuring all 30 NBA teams in "Fortnite," Epic said. Debuting on May 21, 2021 at 8pm ET, players can suit up and rep any of the league's 30 teams. The In The Paint Set includes 31 uniforms, including all 30 NBA teams. "And that's just the beginning," Epic added. "Coming next week, the NBA crosses over into Fortnite Creative. Look for a new blog update showcasing the new NBA Welcome Hub on Tuesday, May 25." Investors in Epic include Tencent (TCEHY), KKR (KKR), Disney (DIS), and Sony (SONY). Reference Link

11:52 EDT Newegg Commerce consummates merger, to trade on Nasdaq under ticker 'NEGG' - Newegg Commerce, formerly Lianluo Smart Limited, announced the closing of the merger with privately-held Newegg Inc. pursuant to the terms of that certain agreement and plan of merger dated October 23, 2020. Immediately after the closing of the merger, the company also consummated the disposition of all of its legacy business, pursuant to the terms of the equity transfer agreement dated October 23, 2020. With the closing, the company has been renamed Newegg Commerce, Inc. and the company's common shares are expected to begin trading under the company's new symbol "NEGG" on or about May 20. "The company decided not to proceed with the $30M offering that was previously contemplated for completion concurrently with the restructure. The offering was no longer necessary for the company to meet NASDAQ initial listing requirements. In addition, recent volatility in the company's public share price and the company's cash position were other factors considered by the company before deciding to forgo the offering. The company may reassess this decision in the future," Newegg stated. Anthony Chow, Global CEO of Newegg Commerce, added: "Becoming a public company is a milestone 20+ years in the making, made possible by the hard work of Newegg's employees, and the support of our many partners, investors and customers. As we enter this new phase as a public company, we're more energized than ever about what the future holds for our company."

11:39 EDT Yalla down 5% after Gotham City Research tweets about short position - Gotham City Research said in a series of tweets: "$YALA reminds us of Let's Gowex and Luckin Coffee $LK. We are short $YALA. [...] Does this $YALA make sense? We think no. World leading revenue growth, and cash flow generation coupled with: A business supposedly based in Africa, CFO/auditor in East Asia, and investor base in North America? Some of you might see a unicorn. We see an ugly duck." In late morning trading following the tweets, shares of Yalla are down 91c, or 5%, to $17.41.

11:35 EDT Mudrick Capital Acquisition Corporation II named a long idea by Citron's Left

11:27 EDT Micron says NAND demand better, supply more disciplined than anticipated - "We started the year a little more bearish on the NAND front. We were concern around over-investment in that space and an oversupply situation. Pricing stabilized but I think we will always be more cautious around NAND given more players in the space. But I think every month we're incrementally more positive how NAND is progressing through the year. I think a lot of that is a function that demand has been better and supply a bit more disciplined than anticipated. Inventories at customer are at pretty normal levels," David Zinsner, Micron's Chief Financial Officer, says. Comments taken from Barclays Americas Select Franchise Conference.

11:23 EDT TJX sees $275M-$325M negative impact to Q2 sales due to store closures

11:13 EDT TJX CEO: In store shopping 'not going away'

11:03 EDT TJX paid fourth 'appreciation bonus' to most employees during pandemic - Comments taken from Q1 earnings conference call.

11:01 EDT Under Armour increases minimum pay rate to $15 per hour - Under Armour announced up to a 50% increase in its minimum pay rate for hourly teammates in the United States and Canada. Hourly rates will increase from a minimum of $10 per hour to $15 per hour, which will go into effect on June 6. As a result, more than 8,000 part-time and full-time teammates, approximately 90% of the Retail and Distribution House workforce, will see a compensation increase. Under Armour currently has more than 3,000 open roles in retail locations and distribution houses, some of which are seasonal and include Sales Teammates, Store Managers and Stock Teammates. All of these roles will start at a minimum of $15 per hour in June.

10:50 EDT Gulfport Energy Corporation trading resumes

10:43 EDT Gulfport Energy Corporation trading halted, volatility trading pause

10:33 EDT M&T Bank appoints Brian Klock as head of markets, investore relations - M&T Bank Corporation announced that Brian Klock joined M&T Bank as senior vice president, May 17, 2021 and work closely with current Head of Investor Relations Don MacLeod as he transitions into retirement. Klock will be named head of Markets and Investor Relations, effective January 1, 2022. Klock joins M&T from Keefe, Bruyette & Woods, where he was managing director and head of Large Regional U.S. Bank Research, covering financial institutions including M&T Bank

10:18 EDT Peloton adds Tread Lock safety feature to Tread+ treadmill - The company said on its support site, "Tread Lock is a safety feature that automatically locks the Peloton Tread+ after you put your Tread+ to sleep or after 45 seconds of inactivity outside of a class...As soon as your Tread+ receives the latest software update, you will be prompted to activate the Tread Lock. Once the passcode has been set, the belt on your Tread+ will automatically lock after 45 seconds of inactivity outside of a class, or after the Tread+ wakes from sleep or restart. You will then have to enter your Tread Lock passcode to unlock the belt and get moving. Tread Lock is an important feature to ensure that your Tread+ is safer than ever before. You will be required to set up Tread Lock." Reference Link

10:03 EDT Microsoft, LaLiga announce expansion of partnership - LaLiga and Microsoft Corp. on Wednesday announced an expansion of their partnership focused on digitally transforming the sports experience globally. The companies will also collaborate on developing technology solutions to the media and entertainment industry through LaLiga's technology offering, LaLiga Tech. As LaLiga's global Tech and Innovation Partner, Microsoft will help develop new and leverage existing solutions that will drive innovation across the sports industry. As part of the collaboration, LaLiga will utilize Microsoft Azure, including AI and machine learning for its LaLigaSportsTV OTT platform and Mediacoach platform, to reinvent interactive audiovisual experiences and formats.

10:00 EDT Concord Medical falls -10.3% - Concord Medical is down -10.3%, or -36c to $3.12.

10:00 EDT Yatsen falls -12.8% - Yatsen is down -12.8%, or -$1.26 to $8.56.

10:00 EDT Scor ADR rises 6.2% - Scor ADR is up 6.2%, or 35c to $5.98.

09:59 EDT Lowe's says 'very committed' to growing market share, operating margin in FY21 - Says "very comfortable" with market share performance, potential gains. Says some inflation pressures, but managing through them. Does not expect inflation to slow demand in 2H21. Says most Pro customers are very busy with large backlogs. Says the better the macro environment performs, the better the company will perform.

09:47 EDT Navios Acquisition falls -12.3% - Navios Acquisition is down -12.3%, or -45c to $3.22.

09:47 EDT BIT Mining Limited falls -18.7% - BIT Mining Limited is down -18.7%, or -$2.56 to $11.14.

09:47 EDT Scor ADR rises 5.5% - Scor ADR is up 5.5%, or 31c to $5.94.

09:43 EDT PGT Innovations adds production facility in Fort Meyers - PGT Innovations is expanding into Fort Myers, with a newly leased production facility to accommodate the firm's continued accelerated growth. The roughly 130,000-square-foot facility is located in the Meridian Center North development at 10400 Meridian Center Parkway. PGT Innovations' manufacturing operations will run 24/7 with various shifts and add 240 new jobs to the region. The new Lee County facility is expected to begin operations in early June 2021.

09:24 EDT Intercontinental Exchange launches UK emissions futures - Intercontinental Exchange, announced that it has launched ICE UK Allowance Futures contracts and today hosted the first auction of the UK Emissions Trading Scheme .Today, 6,052,000 UK allowances were offered for auction and all allowances were sold during the auction. Auctions of UKAs take place every other Wednesday throughout the year, between 12.00 and 14.00 UK time. Auctions have a floor price of GBP 22 per tonne. ICE UK Allowance futures contracts, which launched today, are equivalent to 1000 Allowances. UKA Daily Futures are due to be launched on May 21, 2021. ICE UKA futures trade on ICE Futures Europe and clear at ICE Clear Europe alongside ICE's global environmental complex, including European Union Allowances California Carbon Allowances and California Carbon Offsets .

09:23 EDT Bitcoin briefly falls below $30,000, lowest level since late January

09:23 EDT Coinbase investigating 'intermittent downtime' amid crypto selloff - Coinbase said on its website that it is investigating "intermittent downtime" on its platform. The company noted partial outages on its website, mobile and API. Coinbase shares are down 10% to $216.00 in premarket trading amid the selloff in cryptocurrencies, most notably bitcoin.

09:16 EDT Draganfly signs contract with Integrated Launcher Solutions - Draganfly announced that Integrated Launcher Solutions has signed a contract with Draganfly to provide engineering and development services for a drone-based non-lethal multi-launching system. The contract provides for the development, prototyping, and eventual production of a non-lethal 40mm multi-launching systems that can be mounted and deployed from drones, drone systems, robots, robotic systems, and other stationary platforms or similar systems. The main use case of the launch system is public disturbance management for military and public safety organizations. Draganfly will provide ILS with its development and engineering expertise in connection with the project. As part of the contract Draganfly has provided ILS with strategic vendor financing of $150,000 to assist in the development of the project and in consideration ILS has granted Draganfly a worldwide royalty equal to 8% of the gross revenue received from the project for a period of five years from earlier of the repayment date or maturity date of the loan. The loan is secured against the intellectual property related to the project.

09:12 EDT C&F Financial raises quarterly cash dividend 5.3% to 40c per share - The board of directors of C&F Financial Corporation has declared a regular cash dividend of 40c per share, which is payable July 1, 2021 to shareholders of record on June 15, 2021. This dividend represents a 5.3 percent increase over the prior quarter's dividend amount of 38c per share.

09:10 EDT Good Works Acquisition partner Cipher Mining signs 200 MW provision agreement - Good Works Acquisition partner Standard Power has entered into a contract with Cipher Mining Technologies, a newly formed US-based Bitcoin mining company, to provide hosting capacity that will accommodate 200 MW of power capacity for Cipher's planned operations. Cipher will also have an option to secure additional hosting capacity to allow for another 100 MW of power capacity. Cipher was formed by Bitfury Group as a U.S. blockchain mining company. On March 5, Cipher entered into a definitive agreement for a business combination with Good Works Acquisition. Upon the closing of that transaction, the combined company will be named Cipher Mining and is expected to be listed on the Nasdaq under the new ticker symbol "CIFR". As a stand-alone company, Cipher expects to become a U.S. Bitcoin mining champion by developing approximately 745 MW of mining capacity by 2025. Standard Power will be working closely with Bitfury to secure supply of its advanced BlockBox Air Cooled containerized data centers to host Cipher's miners.

09:08 EDT Evolus appoints Dan Stewart as VP, GM, international - Evolus announced the appointment of Dan Stewart as Vice President and General Manager of the company's International business. Dan was Chief Marketing Officer at Teoxane before starting his own consultancy firm focused within the European aesthetic market.

09:07 EDT Myovant Sciences drops after FDA places partial clinical hold on Phase 3 study - In a regulatory filing, Myovant reported that on May 18, the U.S. Food and Drug Administration informed the company by teleconference that they have placed a partial clinical hold on the Phase 3 SERENE study, MVT-601-050, evaluating relugolix combination tablet for the prevention of pregnancy pending amendment of the study protocol to add bone mineral density monitoring. "Myovant will work expeditiously to implement the requested monitoring and submit the amended protocol to FDA to resolve the partial clinical hold," the company stated in the filing. Shares of Myovant Sciences are down $1.84, or 8%, to $20.76 in pre-market trading following the disclosure.

09:06 EDT ZoomInfo partners with Snowflake to centralize and streamline data delivery - ZoomInfo (ZI) announced a partnership with Snowflake (SNOW), the Data Cloud company, in which ZoomInfo will join Snowflake Data Marketplace to centralize and streamline data delivery. Customers can now use Snowflake's platform to integrate ZoomInfo's industry-leading company and business contact data into their technology stacks-with no additional integration or extract transform load required-and generate insights at scale. Data is constantly changing, and what is accurate one day is outdated the next. Nearly 30 percent of personnel change jobs each year, and companies are always evolving in some manner. Sellers and marketers need a seamless way to accurately capture, unify, and share that data. Those that don't take action to stay connected to this ever-changing business landscape put themselves at risk of disengaged audiences, missed opportunities, and lost revenue. Joint customers can leverage prebuilt ZoomInfo data sets in Snowflake Data Marketplace or work with ZoomInfo's Data Services team to create custom data sets that meet their specific needs. Customers have more than 300 data attributes to choose from to help them identify their ideal buyers. They can target companies based on firmographic details like revenue, employee size, industry, and location, as well as events like funding rounds, product launches, M&A transactions, buying intent signals, additions of new technologies, and executive hires. "This partnership can deliver data accuracy with near-instant updates," said Chris Degnan, Snowflake's Chief Revenue Officer. "As a result, ZoomInfo's data sets can help enterprises develop their business intelligence strategies with exactness. Together, ZoomInfo and Snowflake can help companies improve their data delivery from the cloud and power their go-to-market motions more effectively." ZoomInfo ensures accuracy of its data over time with real-time updates, eliminating data decay with continuous enrichment services directly within Snowflake. ZoomInfo prioritizes GDPR and CCPA compliance, and maintains its rigorous data privacy and security practices through all data provided via partnerships.

09:04 EDT Galaxy Gaming secures rights for Perfect Pairs in UK - Galaxy Gaming announced that they have reached an agreement with John Wicks, creator of Perfect Pairs, to exclusively provide a Perfect Pairs live gaming progressive jackpot on land-based table games in the United Kingdom. This development builds upon Galaxy Gaming's continued success with Perfect Pairs in the iGaming space through its wholly-owned subsidiary, Progressive Games Partners. Perfect Pairs and Galaxy Gaming's world-famous 21+3 are the most popular Blackjack side bets in both the land-based and iGaming space in the UK. This new partnership capitalizes on the game's existing prominence and highlights the power of Galaxy Gaming's progressive jackpot system to add value to the player experience and increase revenue opportunity for land-based casino operations.

09:04 EDT HP Inc. appoints Greg Baxter as CTO - HP Inc. (HPQ) announced two executive leadership appointments that support the company's long-term growth strategy and strategic priorities. Greg Baxter has been named Chief Transformation Officer. In this role, Baxter will lead and cultivate the company's digital capabilities to better serve customers while also significantly reducing operating costs. He joins HP from MetLife (MET) where he served as Chief Digital Officer. Baxter succeeds Marie Myers, who was named HP's CFO earlier this year and had also been serving as Acting Chief Transformation Officer. Didier Deltort has been named President of Personalization & 3D Printing. Reporting to Sarabjit Singh Baveja, HP's Chief Strategy & Incubation Officer, he will lead global end-to-end business management to drive commercial growth, create new businesses, and disrupt industries with HP 3D Printing technology and intellectual property. Deltort joins the company from Zimmer Biomet (ZBH) where he served as President of the Europe, Middle East and Africa business.

09:02 EDT Arthur J. Gallagher acquires Garner & Glover Company - Arthur J. Gallagher acquired Rome, Georgia-based Garner & Glover Company. Terms of the transaction were not disclosed. Founded in 1874 and operating under its current name since 1926, Garner & Glover is an independent agency offering business and personal property/casualty, life and benefits products, as well as athletics, wellness and risk management services, to clients throughout the U.S. Matt Sirmans, Chuck Shaw and their associates will continue to operate from their current location under the direction of Peter Doyle, head of Gallagher's Southeast region retail property/casualty brokerage operations, and John Tournet, head of Gallagher's Southeast region employee benefits consulting and brokerage operations.

08:48 EDT Canacol says Colombia gas sales, drilling operations 'remain uninterrupted' - Canacol Energy provides the following information concerning its operations in Colombia. The company said, "Despite the civil disturbances occurring in Colombia related to the national strike, Canacol's gas salesand drilling operations remain uninterrupted. Given that Canacol's gas sales are delivered via pipeline, the transportation and delivery of gas to its clients has been uninterrupted. Realized contractual natural gas sales have averaged 172 million standard cubic feet per day for the period May 1 to May 17, 2021. Outside of the major cities, the majority of blockades are occurring in the oil producing Llanos, Middle Magdalena, and Putumayo basins. As recently announced by other oil focused Colombian producers, the blockades have been disruptive to transportation of crude oil, drilling and workover equipment, and personnel. The Corporation's operations, which are located in the Lower Magdalena basin where there are few blockades, have not been adversely affected."

08:45 EDT Atlas Corp.'s Seaspan announces delivery of two 8,500 TEU containerships - Seaspan, a wholly owned subsidiary of Atlas Corp., announced that it has accepted delivery of two quality 8,500 TEU scrubber-fitted containerships on long-term charter with a global liner.

08:40 EDT Diana Shipping announces time charter contract for M/V Astarte - Diana Shipping entered into a time charter contract with Mitsui O.S.K. Lines, Ltd., for one of its Kamsarmax dry bulk vessels, the m/v Astarte. The gross charter rate is $25,000 per day, minus a 5% commission paid to third parties, for a time charter period until minimum November 1, 2021 up to maximum December 15, 2021. The charter is expected to commence tomorrow. The m/v Astarte is currently chartered, as previously announced, to Aquavita International S.A., at a gross charter rate of $11,750 per day, minus a 5% commission paid to third parties. The "Astarte" is a 81,513 dwt Kamsarmax dry bulk vessel built in 2013. The employment of "Astarte" is anticipated to generate approximately $4.03 million of gross revenue for the minimum scheduled period of the time charter.

08:40 EDT Veru enrolls first patient in Phase 3 trial of sabizabulin - Veru announced that it has enrolled the first patient in its Phase 3 clinical trial of sabizabulin, a novel, proprietary, oral cytoskeleton disruptor with anti-inflammatory and anti-viral properties, to combat the effects of COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2.

08:39 EDT Live Ventures extends stock buyback program until June 1, 2024 - Live Ventures Incorporated previously announced that its Board of Directors has extended the stock buyback program until June 1, 2024. The program authorizes the company to buy up to $10M of its outstanding shares of common stock on the open market at prevailing prices. Of that amount, approximately $6.7M remains available as of today for this purpose. Since inception of the stock buyback program in 2018, 418 thousand shares of LIVE stock have been repurchased at an average price of $7.70 and, as of the last trading day prior to the issuance of this press release, the company's stock closed at $41.75 per share. Repurchases under the program are funded by cash on hand and cash generated by operations of the company's core businesses.

08:38 EDT Mobileye announces deal with Toyota for ADAS technology - Mobileye, an Intel (INTC) Company, announced in a blog post earlier this week: "Over the past two decades since our founding, Mobileye has worked with the vast majority of the world's leading automakers to help make their vehicles and the roads on which they drive safer. Now we're pleased to count the largest automaker in the world among our customers as Toyota and Mobileye have signed a pivotal new deal to deploy our ADAS tech in an array of new vehicles in the coming years. With today's announcement, Toyota joins a substantial and growing list of automotive manufacturers that have placed their trust in Mobileye technology to power their advanced driver-assistance systems." Intel noted that ZF and Mobileye have been chosen by Toyota Motor (TMC) to develop advanced driver-assistance systems, or ADAS, for use in multiple vehicle platforms starting in the next few years. "As part of the agreement, ZF, one of the world's largest producers of automotive cameras driven by Mobileye technology, will also supply its Gen 21 mid-range radar and be responsible for the integration of camera and radar in Toyota vehicles," Intel stated. Reference Link

08:36 EDT Blackstone Mortgage names President, Katie Keenan CEO - Blackstone Mortgage Trust announced that Katie Keenan, BXMT's President, has been named Chief Executive Officer of BXMT, effective June 30, 2021. She will succeed Steve Plavin, who remains a key member of the Blackstone Real Estate Debt Strategies leadership team and will oversee BREDS' best-in-class European platform. In connection with her appointment, Ms. Keenan will join the BXMT Board of Directors. Mike Nash continues in his role as Executive Chairman of the Board of Directors. This announcement marks the culmination of a multi-year transition plan. Over the past few years, Ms. Keenan has taken on increasing responsibility within BXMT, playing an integral role in managing the company's investment strategy and operations. Prior to being appointed BXMT's President in February 2020, she served as BXMT's Executive Vice President for Investments. Since Katie joined the management team of BXMT in 2018, the BXMT portfolio has grown by over 50% to $18.7 billion today, with consistently strong credit performance and returns. Steve has led BXMT since its re-IPO in 2013, overseeing a period of significant growth and strong performance for the business. The REIT has grown into a world-class, leading commercial mortgage lender with an $18.7 billion portfolio and $4.6 billion market cap and yielded total returns to shareholders of 10.8% annualized.

08:34 EDT Target sees FY CapEx about $4B

08:32 EDT Toyota to suspend three production lines at two plants in Japan due to shortages - Toyota announced adjustments to domestic production in June due to parts shortages as of May 18, stating that "due to parts shortage, adjustments will be made to production operations of plants for completed vehicles in Japan." For June, Toyota announced production suspension for three production lines at two plants among a total of 29 lines at 14 plants. Reference Link

08:28 EDT Osisko Development announces drilling results from Cariboo project - Osisko Development is pleased to announce drilling results from the 200,000-meter 2021 exploration and category conversion drill program campaign at its Cariboo Gold Project in central British Columbia. A total of ten diamond drill rigs are currently active on the Cariboo Project. Lowhee Zone Overview: Two rigs currently operating on Lowhee Zone located on Barkerville Mountain. Recent results include holes BM-21-001 to BM-21-018. Mineralized vein corridors are currently defined along 650 meters strike by 350 meters in the sandstone to a depth of 275 meters and is open in all directions. Lowhee is interpreted to be the strike extension of Cow Mountain as shown in recent results. Based on the Mineral Resource Estimate dated October 5, 2020, at a cut-off grade of 2.10 g/t Au, the Lowhee Zone contains 46,000 oz in the indicated category and 105,000 oz Au in the inferred category based on only 23 drill holes. A total of 73 drill holes have since been drilled in the Lowhee Zone. Recent Drilling Highlights: 13.22 g/t Au over 2.60 meters in hole BM-21-001; 6.14 g/t Au over 6.55 meters in hole BM-21-002 including; 43.70 g/t Au over 0.60 meter in hole BM-21-002; 70.90 g/t Au over 1.00 meter in hole BM-21-013; 6.26 g/t Au over 7.60 meters in hole BM-21-015; 7.97 g/t Au over 4.05 meters in hole BM-21-016 including; 58.80 g/t Au over 0.50 meter in hole BM-21-016; 41.39 g/t Au over 1.10 meters in hole BM-21-017 including; 70.20 g/t Au over 0.60 meter in hole BM-21-017. Mineralized quartz veins on Cariboo are overall sub-vertical dip and northeast strike. Vein corridors are defined as a high-density network of mineralized quartz veins within the axis of the last folding event's folds and hosted within a brittle meta-sandstone or calcareous meta-sandstone. Vein corridors are modelled at a minimum thickness of 2 meters and average about 4.5 meters true width. Individual mineralized veins within these corridors have widths varying from centimeters to several meters and strike lengths from a few meters to over 50 meters. These corridors have been defined from surface to a vertical depth averaging 300 meters and remain open for expansion at depth and along strike. Gold grades are intimately associated with quartz vein-hosted pyrite as well as pyritic, intensely silicified wall rock haloes in close proximity to the veins. True widths are estimated to be 60% to 75% of reported core length intervals. Intervals not recovered by drilling were assigned zero grade. Top cuts have not been applied to high grade assays.

08:26 EDT Target: 100 Ulta shop-in-shops slated to launch in 2H

08:24 EDT Target: Private label brands grew about 36% in Q1

08:22 EDT Sterling Bancorp makes strategic investment in Finitive - Sterling Bancorp has made a capital investment in Finitive, a private credit marketplace that provides institutional investors with direct access to private credit transactions. Finitive will use the new capital to accelerate the growth of its automated platform for facilitating private credit transactions. Finitive provides investors with access to a multi-trillion-dollar market that spans a broad spectrum of sectors, including specialty finance, online lending, marketplace lending and private credit funds.

08:20 EDT Vera Bradley appoints Nancy Twine to board of directors - Vera Bradley announced that Nancy Twine, Founder and CEO of Briogeo Hair Care, has been nominated to join its Board of Directors. Twine will replace director Michael Miller upon his retirement from the Vera Bradley, Inc. Board in June 2021, and with this appointment, the Company will have 60% female board representation and be one of just a few public companies with a female majority board.

08:17 EDT Infinera introduces suite of XR optics-powered coherent pluggable solutions - Infinera announced that it has expanded its portfolio of open optical networking solutions with a suite of coherent optical pluggables designed to seamlessly address point-to-point and point-to-multipoint transport applications from the network edge to the core. Leveraging innovative XR optics technology, Infinera's new suite of vertically integrated ICE-XR pluggables will offer network operators the performance, scale, and efficiency critical to the delivery of differentiated 5G, enhanced broadband, and next-generation cloud and business services. ICE-XR pluggables will support a range of transport rates, including 100G, 400G, and 800G, and utilize industry-standard form factors such as QSFP-28, QSFP-DD, and CFP2 to enable ease of deployment in a wide variety of router and transport devices. Initial ICE-XR pluggables are scheduled for release in 2022.

08:14 EDT Siyata Mobile receives non-compliance notice from Nasdaq - Siyata Mobile announces that, on May 18, 2021, it received a notice from the Nasdaq Stock Market indicating that, as a result of not having timely filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2020, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. Nasdaq requires that the Company submit a plan no later than July 16, 2021 to regain compliance. If Nasdaq accepts the plan, Nasdaq can grant the Company an extension of up to 180 calendar days from the due date of the Form 20-F to regain compliance. The Company is working diligently and plans to file the Form 20-F as soon as practically possible. The Notice has no immediate impact on the listing of the Company's securities, which will continue to trade on Nasdaq, subject to the Company's compliance with other continued listing requirements of Nasdaq.

08:13 EDT Histogen, Amerimmune report publication on emricasan in COVID-19 - Histogen and its partner, Amerimmune reported the publication of the potential utility of emricasan in COVID-19 in Allergy, the official Journal of the European Academy of Allergy and Clinical Immunology. Amerimmune, in collaboration with Dr. Raavi Gupta from SUNY Downstate Medical Center and Dr. Lishomva Ndhlovu from Weill Cornell Medicine, demonstrated the impact of caspases in multiple blood cells beyond the acute stage of the disease. Their research concluded that caspases are elevated in patients with co-morbidities and persisted into much later stages of the disease, also referred to as long COVID. Moreover, the results were not just limited to the elevation of caspase-1 in white blood cells. There was also an elevation of caspase-3 in red blood cells. These findings have potential implications to understand the pathogenesis of complications of SARS-CoV2 infection such as extensive blood clot formation, resulting in significant morbidity and mortality. The collaborative work of SUNY Downstate and Weill Cornell Medical Center with Amerimmune demonstrated how in certain individuals regarded as "high risk", such as asthma, immune deficiencies and chronic sinopulmonary disease, there is already increased baseline caspase-1 expression, potentially setting the stage for complications if they were to be infected with SARS CoV2. All the assays used in this study were developed and validated by Amerimmune. This study now leads to more research opportunities to explore why some individuals develop worse outcomes, whereas some others remain asymptomatic. Most importantly, the team showed that Emricasan, a pan-caspase inhibitor, can effectively reduce the caspase expression in in vitro, paving the way to the use of pan-caspase inhibition as a treatment modality in COVID-19. "Emricasan is a small molecule pan-caspase inhibitor that is administered orally, which has been shown to reduce caspase related inflammation in tissues. This therapeutic modality could address the events at the onset of the COVID-19 process and may have the potential to prevent the down-stream COVID-19 related complications," said Oral Alpan, MD, CEO of Amerimmune. "The findings from this important research support the potential of emricasan as a treatment option for COVID-19 in the acute and long-haul phases of the disease," said Richard Pascoe, President and CEO of Histogen. "We look forward to the anticipated completion of our ongoing Phase 1 Study in mild- symptomatic COVID-19 patients at SUNY Downstate Medical Center, in the second quarter of 2021."

08:11 EDT TJX says Q2 comparable store sales trends remain similar to Q1 - The company said, "For the start of the second quarter of Fiscal 2022, overall open-only comp store sales trends remain similar to the first quarter. In the second quarter of Fiscal 2022, the Company expects total sales, pretax margin, and earnings per share to be negatively impacted from the temporary store closings described above. Due to the continued uncertainty of the current environment, the Company is not providing financial guidance at this time."

08:10 EDT HiberCell announces $30M debt facility from Hercules Capital - HiberCell announced that it has completed a Series B financing round for gross proceeds of $67.4 million. Concurrent to this financing, HiberCell closed on a $30 million debt facility with Hercules Capital. The Series B round included new investors Huizenga Capital Management, Monashee Investment Management, funds managed by Tekla Capital Management LLC, Hercules Capital, Mount Sinai Innovation Partners and other undisclosed investors. Returning investors, including ARCH Venture Partners, Magnetic Ventures, Bristol Myers Squibb, Trinitas Capital, and others from the Series A syndicate, also participated in the round. HiberCell will use the proceeds of the Series B financing and debt facility to support the clinical development of novel therapeutics targeting stress biology and innate immunity to address the role these play in prevention of cancer recurrence and metastasis.

08:09 EDT Taoping launches Taoping Digital Assets subsidiary - Taoping announced the establishment of its majority-owned subsidiary, Taoping Digital Assets. Taoping Digital Assets is a Hong Kong limited liability company and its main business is expected to be managing Taoping G Cloud Hong Kong Data Center and providing support to the Company's five business divisions from Hong Kong. Mr. Chi To Ip was appointed as president of Taoping Digital Assets. The launch of Taoping Digital Assets is expected to further enhance the Company's international competitiveness and overseas supply chain, and advance TAOP's global development plan.

08:07 EDT aTyr Pharma presents preclinical research on ATYR2810 - aTyr Pharma announced that it will present a poster and participate in a live Q&A session at the Virtual Keystone Symposia on Cancer Stem Cells: Advances in Biology and Clinical Translation, which is being held May 19 - 21, 2021. The abstract and poster are available on the Keystone Symposia website. The poster presents preclinical findings demonstrating that ATYR2810, a Neuropilin-2 antibody, selectively blocks the NRP2/VEGFR signaling axis and sensitizes patient-derived xenograft models of triple-negative breast cancer to chemotherapy. Furthermore, gene expression data from TNBC xenograft samples and patient derived organoids show that ATYR2810 downregulates several cancer stem cell and epithelial-mesenchymal transition markers. "We are very excited about these recent findings, which build upon our understanding of the mechanistic impact of blocking the NRP2/VEGF signaling axis with ATYR2810 on aggressive tumor cells and demonstrate the molecular basis for its selectivity by directly obstructing the VEGF binding site on NRP2," said Leslie Nangle, Ph.D., Vice President, Research at aTyr. "The research presented here, which includes data in patient-derived xenografts, suggests that ATYR2810's ability to effect EMT and cancer stem cell properties may be one mechanism by which it mediates the anti-tumor effects we have observed. This work moves us closer to identifying the underlying characteristics within a tumor that may confer responsiveness to treatment with ATYR2810."

08:06 EDT Limestone Boat Company enters partnership with Vision Marine Technologies - The Limestone Boat Company announces a partnership with Vision Marine Technologies to produce its proprietary E-Motion electric propulsion powertrain option for select Limestone and Aquasport brand models.

08:05 EDT JetBlue announces nonstop service to two London airports - JetBlue announced it will make its entrance into the transatlantic market with nonstop service between New York's John F. Kennedy international Airport and London Heathrow Airport starting August 11. The company will further enhance its U.S. and U.K. schedules with nonstop service between New York-JFK and London Gatwick Airport starting September 29. London service from Boston will start in Summer 2022.

08:03 EDT Marimaca Copper reports results from mapping, sampling at Cindy Target - Marimaca Copper is pleased to announce the results from underground mapping and sampling at the Cindy Target, which indicate broad zones of higher-grade mineralization. Highlights: Cindy is located approximately 5km north of the Company's flagship Marimaca Oxide Deposit. Underground channel sampling defines broad zones of higher-grade mineralization including: 38m @ 0.90% CuT, 112m @ 0.41% CuT, 36m @ 0.60% CuT, 48m @ 0.90% CuT and 160m @ 0.59% CuT; Historical underground workings selectively exploited high grade copper mineralization in magnetite breccias Consists primarily of copper oxides atacamite, brochantite and chrysocolla with some wad; Drilling commenced at the end of April targeting a 1,300m long complex with several magnetite breccias with the potential to host high grade copper mineralization; Targeting sulphide extensions to historical underground workings as well as exposed oxides; Progressing well with first results expected by end of May 2021. Sergio Rivera, VP Exploration of Marimaca Copper, commented: "We have now completed channel sampling of artisanal, underground, workings at Cindy. These are relatively shallow historic workings targeting high grade oxides and extend vertically over four levels, approximately 20 meters apart and with over 200 meters of strike length resulting in several hundred meters of drifts. Sampling highlighted broad zones of continuous copper oxide mineralization, including one area with 160 meters at 0.59% CuT, which had several samples greater than 1% CuT. The artisanal miners were targeting grades significantly in excess of 1% CuT, and the mineralization that has been left behind is extensive. We have also confirmed the importance of magnetite breccias, which control the highest-grade copper mineralization and were targeted by the artisanal miners. Importantly, we have found evidence of several magnetite breccias outside the area of the underground workings which will be targeted in the current drill program."

07:59 EDT Unisys Dutch Pension Plan transferred to multi-employer fund - Unisys' primary pension plan related to its Dutch subsidiary has been transferred to a multi-client circle within a multi-employer fund effective May 1. This transaction results in the removal of all pension liabilities related to the plan, valued at approximately $550M, from the company's balance sheet. Unisys anticipates that this action will result in a one-time, non-cash, pre-tax settlement charge of approximately $185M. The action, along with the company's recently announced lump-sum cash-out offer and a separate annuity purchase for its U.S. pension plans, has resulted in the removal of a total of approximately $1.1B of pension liabilities from the Unisys balance sheet.

07:45 EDT ArcelorMittal announces shareholding notifications from Societe Generale - ArcelorMittal (MT) announces that on 19 May 2021 it received two shareholding notifications from Societe Generale (SCGLY). The notifications were made to reflect the entry into by Societe Generale SA mainly of various financial instruments. According to the notifications, the following thresholds of voting rights were reached: 5.10% on 14 May 2021, and 4.72% on 17 May 2021. These notifications do not require any adjustments to the disclosure of the Company regarding its shareholding structure as the Company only reports shareholding thresholds above 5% on its website since, following the above-mentioned 17 May 2021 notification, Societe Generale SA is again below this threshold.

07:36 EDT Osino Resources provides update on drilling at Twin Hills project - Osino Resources Corp. is pleased to provide an update on infill drilling at its Twin Hills Gold Project in the Erongo Region of Namibia, including more specifically high-grade intercepts at its recent discovery at Clouds East. The Twin Hills Gold Project maiden resource was released on April 12th, 2021 including 0.43Moz @ 1.00g/t in the Indicated category and 1.47Moz at 1.08g/t in the Inferred category with a cut-off grade of 0.5g/t. The in-fill drill program is aimed at converting the bulk of the mineralization to the Indicated and Measured Categories and includes approximately 42,000m of drilling to be completed by July 2021. The first resource drill program included 69,000m of drilling and was carried out at a collar spacing of 50m x 50m with small areas of denser drilling in zones of geological complexity. The in-fill drill program commenced in March 2021 and is being carried out on a staggered 50m x 50m pattern, resulting in an effective maximum drill spacing of approximately 32m to 35m. Certain areas may be drilled to a tighter spacing to ensure a minimum Indicated resource classification to be achieved before the end of 2021. There are currently 4 reverse-circulation rigs drilling the holes of up to 220m in depth around the margins of the modelled pit at THC, Bulge and Clouds and 5 diamond rigs drilling the in-fill holes of greater than 220m in the center of the pits. The in-fill program includes a total of approximately 42,000m to be completed by July 2021 with assay results expected around 2 months later. In-fill assays received since March 30, 2021 include the best intercept to date at Clouds with most of the other assays still outstanding. OKR211 and OKR152 are shallower holes to the south on the same section line, which were completed recently. Assays for these holes are expected to be received shortly. Additional deeper and lateral step-out holes, outside of the resource envelope, have also been completed in order to test down-dip and strike extensions of the known Clouds orebody. In-fill assays at the Bulge and Twin Hills Central confirm the consistency and grade of mineralization that was indicated in the first round of drilling with intercepts of up to 186m wide. Deeper in-fill holes at the Bulge and THC are being drilled with diamond rigs as experience to date has shown that RC drilling tends to start deviating significantly at a depth of greater than 220m. A brownfields exploration program to test 14 high-priority targets was announced on March 25, 2021. The targets include gold-in-calcrete, magnetic and IP anomalies within 10km of THC which are being tested as part of this ongoing drill program. Of the planned 25,000m of drilling, approximately 17,889m has already been completed to-date with assay results expected to start arriving within the next two weeks.

07:33 EDT Navidea receives drug delivery vehicles patent from USPTO - Navidea announced that the U.S. Patent and Trademark Office, or USPTO, issued to Navidea U.S. patent 11,007,272, entitled "Compounds and Methods for Diagnosis and Treatment of Viral Infections," with protection to October 7, 2037. This patent protects the use of Navidea's mannosylated dextran-based drug delivery vehicles to deliver small molecule therapeutic payloads as possible therapies for a variety of diseases caused by a group of viruses known as flaviviruses. Specific flaviviruses disclosed in the patent include those that cause dengue, yellow fever, and Zika fever.

07:32 EDT Cytokinetics, ALS Association renew partnership in fight against ALS - Cytokinetics, Incorporated and The ALS Association announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the 2021 ALS Roundtables and ALS Focus, a patient and caregiver led survey program to learn about individual experiences with ALS. Cytokinetics is also a Platinum Level Sponsor for initiatives led by The ALS Association Golden West Chapter, including grant funding for care services for people with ALS in the Bay Area. In 2021, Cytokinetics will continue to support and participate in several virtual events and initiatives with The ALS Association focused on continuing disease awareness and education, including the 2021 ALS Roundtables, during which patients, caregivers, industry, researchers, insurers and clinicians convene to discuss various topics of importance to the ALS community.

07:21 EDT Renalytix, Atrium Health, Wake Forest Baptist Health partner for kidney health - Renalytix AI, Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine announced a partnership to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The KidneyIntelX bioprognostic platform for early-stage diabetic kidney disease risk assessment will be available through Atrium Health's electronic health record system, providing access to primary care physicians, endocrinologists, nephrologists and care teams throughout 37 hospitals and more than 1,350 care locations across the Carolinas and Georgia. Charlotte, North Carolina-based Atrium Health serves more than 7 million people in the region, providing care under the Wake Forest Baptist Health name in the Winston-Salem, N.C. region and Atrium Health Navicent in Georgia. The partnership with Renalytix enables focused population health initiatives in kidney disease and will provide real-world evidence of optimized delivery of care, improved quality of life, and reduced healthcare costs. Renalytix will co-locate personnel in Winston-Salem to support the partnership program with Wake Forest School of Medicine at the Innovation Quarter's iQ Healthtech Labs, which is the core industry partnership hub of the innovation district. Renalytix and Atrium Health believe the partnership is closely aligned with the core precision medicine and healthy aging sectors that are a focus of iQ Healthtech Labs. The new program initially targets diabetes-associated kidney disease, a critical healthcare need in the region served by Atrium Health and designated by the Centers for Disease Control and Prevention as the "diabetes belt" and the "kidney disease belt." In this region in particular, but also nationally and internationally, costs and patient suffering related to diabetes and its associated complications are increasing at unsustainable rates. The partnership also powers a five-year, multi-center evidence development program across the region, in which patients with chronic kidney disease will receive the KidneyIntelX test as part of a comprehensive care solution to drive quantifiable improvements in patient outcomes. KidneyIntelX will also be made broadly available to patients with both private and government insurance, including Medicare beneficiaries under the Medicare Coverage of Innovative Technology expected to be fully implemented in December 2021. RenalytixAI will be providing financial support to Atrium Health in the form of collaborative research and development, digital health technology deployment, education program delivery and third-party resources in each of these critical areas.

07:18 EDT Silence Therapeutics announces data from GEMINI Phase 1 study of SLN124 - Silence Therapeutics announced topline data from the GEMINI phase 1 study of its wholly owned product candidate, SLN124, in healthy volunteers. SLN124, an siRNA which targets TMPRSS6, is in development for the treatment of iron-loading anemia conditions, thalassemia and myelodysplastic syndrome. The GEMINI phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study evaluated the safety and tolerability of SLN124 in 24 healthy volunteers. Pharmacokinetic parameters and pharmacodynamic biomarkers of iron metabolism were also measured to assess reduction in iron. Initial data from the study showed all doses of SLN124 were generally well-tolerated with no serious or severe treatment emergent adverse events or TEAEs leading to withdrawal. TEAEs did not appear to be dose dependent and the majority were mild, including transient injection site reactions which resolved without intervention. Notably, up to an approximate four-fold increase in average hepcidin and 50% reduction in plasma iron levels were also observed after a single dose of SLN124. Effects on hepcidin and iron appear to be dose dependent and were still observed at the end of the 8-week study at all dose levels, indicating a sustained and long duration of action. These clinical data support preclinical findings which demonstrated SLN124 effectively improved red blood cell production and reduced anemia by increasing levels of hepcidin - a key natural regulator of iron balance and distribution in the body. The Company expects to measure red blood cell production and effects on anemia in the ongoing GEMINI II phase 1 study of SLN124 in people with thalassemia and MDS, who unlike healthy volunteers have significantly elevated iron levels. Silence expects to present full data from the GEMINI phase 1 study of SLN124 in healthy volunteers at an appropriate scientific meeting later this year. In addition, the Company plans to report data from the single-ascending dose portion of the ongoing GEMINI II phase 1 study of SLN124 in people with thalassemia and MDS in the second half of this year. SLN124 has Orphan Drug Designation for both conditions and rare pediatric disease designation for beta thalassemia.

07:16 EDT Landos Biopharma appoints Tim Mayleben to board of directors - Landos Biopharma, Inc (LABP) announced the appointment of Tim Mayleben to its Board of Directors. Mayleben was most recently the President, CEO and Director of Esperion Therapeutics (ESPR), a pharmaceutical company focused on the development and commercialization of therapies for the treatment of patients with elevated levels of LDL-cholesterol.

07:13 EDT Trevena announces presentations on OLINVYK health economic models - Trevena announced two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research 2021 Annual Conference. The conference is being held virtually from May 17th to 20th, 2021. The posters highlight two health economic models developed for OLINVYK injection, which estimate the budget impact of OLINVYK compared to IV morphine when used on-demand in a hospital setting for postoperative pain. Both models were also presented at the Academy of Managed Care Pharmacy 2021 Annual Meeting. The base case model calculates a ~$230,000 decrease in total cost of care per 1,000 patients associated with OLINVYK, compared to IV morphine. When limited to patients who are both elderly and obese, the expected savings associated with OLINVYK increase to ~$364,000 per 1,000 patients, with the total cost of care associated with IV morphine exceeding $1.25M per 1,000 patients. These cost savings are due to reduced AEs for OLINVYK-treated patients, as observed in the Phase 3 pivotal trials, and using a conservative, low-end estimate of AE costs based on government and published literature sources.

07:10 EDT Flora Growth forms Flora Lab manufacturing division - Flora Growth Corp. announced the formation of Flora Lab, a consolidated manufacturing division that will be comprised of the recently acquired Quipropharma Lab and the strategic business combination of its two medical-focused divisions, Cronomed and Breeze Laboratory. The newly formed division is underpinned by Quipropharma Lab, a modern 16,000-square-ft manufacturing facility and holds multiple GMP certifications with a diversified portfolio with over 190 products and 63 OTC products registered and licensed with INVIMA. With both branded products and a suite of wholesale white-label clients, Flora Lab is expected to serve as the manufacturing centre for Flora. The addition of the new manufacturing certifications and production capacity from Quipropharma when combined with Breeze and Cronomed's existing distribution network is expected to increase Flora's overall revenue potential. Looking forward, the division will be focused on expanding its 1,500+ distribution channels and developing new cannabinoid and non-cannabinoid containing products to sell to its network of pharmacies and wholesale clients. Some highlights from Quipropharma Lab include: The laboratory is a modern 16,000-square-ft facility. The laboratory holds 2 GMP certifications: Phytotherapeutics; Dietary Supplements. The laboratory has the capability to produce CBD-containing products. The laboratory holds 18 domestic clients and sells branded products along with white-label products.

07:08 EDT Chart Industries completes EUR6.5M minority investment in Cryomotive - Chart Industries announced the completion of a minority investment in Cryomotive GmbH for the amount of EUR6.5M and offers an in-kind contribution to develop Cryomotive's cryogenic storage and refueling technology. The company said, "Cryomotive is a leading green-tech mobility startup in Germany developing a disruptive clean hydrogen storage and refueling technology platform focused on compressed cold hydrogen and cryogenic high-pressure storage. Cryomotive's proprietary CcH2 CRYOGAS technology aims to decarbonize long-haul commercial vehicles while keeping the range and fueling times similar to diesel powered vehicles and reaching parity in costs of ownership before 2030. The market for fuel cell powered long-haul commercial vehicles is expected to rapidly grow to more than 700,000 units by 2035 in Europe and China alone, and this does not include additional application areas such as coach buses, trains, ships and aircraft." Cryomotive and Chart have entered a strategic partnership, including Chart's minority investment and in-kind contribution, as well as a commercial agreement. The development and supply partnership will enable Cryomotive to leverage its proprietary technology jointly with Chart's established position in the refueling and hydrogen station market. As the options for heavy duty hydrogen fueling continue to be analyzed by the end users, this supply partnership provides another option for Chart's customers, as Chart is now offering both liquid hydrogen, as well as CcH2 cryogenic high-pressure refueling and storage. As the result of this investment and agreement, Chart is increasing its hydrogen addressable market by $100M to include the application of the liquid hydrogen pump, hydrogen storage tanks and transportation systems specifically on Cryomotive applications in the next five years.

07:06 EDT Purple Biotech appoints Suzana Nahum-Zilberberg to board of directors - Purple Biotech announced the appointment of Suzana Nahum-Zilberberg to its Board of Directors. Ms. Nahum-Zilberberg currently serves as Vice Chairman of the Board of BioLight Life Science, which is traded on the Tel Aviv Stock Exchange, and from 2011 to 2020 served as the CEO of BioLight. Purple Biotech's Board of Directors now includes eight members, six of whom are independent. Ms. Nahum-Zilberberg will serve as a member of the third class of the Board of Directors until the annual general meeting of shareholders to be held in 2021, at which time she may stand for reelection.

07:05 EDT ZIM Integrated declares special dividend of $2.00 per share - Zim Integrated declared a special cash dividend of $2.00 per ordinary share that will be paid on September 15 to all holders of record of ordinary shares as of August 25.

07:01 EDT LogicBio Therapeutics promotes Daniel Gruskin, MD, to Chief Medical Officer - LogicBio Therapeutics announced the promotion of Daniel Gruskin, MD, as chief medical officer. Dr. Gruskin most recently served as senior vice president and head of clinical development. The company also announced the appointment of Stephen Boyer, PhD, as vice president of regulatory and quality affairs, and Peter Pechan, PhD, as vice president of gene therapy, who will support progress in the Phase I/II SUNRISE clinical trial of LB-001, the company's investigational treatment for methylmalonic acidemia based on LogicBio's proprietary gene insertion platform, GeneRide, and gene therapy programs leveraging the Company's sAAVy platform.

06:59 EDT EU passenger car registrations up 218.6% in April - In April, new car registrations surged by 218.6% in the European Union because of last year's low base of comparison, reported the European Automobile Manufacturers Association. "Despite this big percentage increase, last month's sales volume was almost 300,000 units lower than that recorded in April 2019," the group said. "From January to April 2021, EU demand for passenger cars increased by 24.4% to reach 3.4 million units registered in total, with the last two months providing a substantial boost," said the ACEA. Publicly traded automakers include Daimler AG (DDAIF), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), Stellantis (STLA), Tesla (TSLA), Toyota (TM) and Volkswagen (VWAGY). Reference Link

06:56 EDT TAT Technologies announces repair facility partnership with Lufthansa Technik - TAT Technologies announced a partnership with Lufthansa Technik Shenzhen to establish a repair facility in China for maintenance, repair and overhaul, or MRO, of aircraft heat transfer components. The facility will support operators in the Asia Pacific region. In the interim, the companies have begun supporting operators in China through TAT Technologies. With the partnership, the companies aim to establish a position in China and are looking forward to starting the new venture.

06:50 EDT Sonoco ThermoSafe, Cathay Pacific Cargo expand partnership - Sonoco ThermoSafe, a unit of Sonoco, and Cathay Pacific Cargo announced an expanded global partnership agreement for the leasing of the new Pegasus ULD temperature controlled bulk shipping container. The agreement enables pharmaceutical freight forwarders to lease Pegasus ULD containers directly from Cathay Pacific Cargo.

06:46 EDT Cathie Wood's ARK Investment discloses 47K shares of Tesla bought on Tuesday

06:42 EDT Cathie Wood's ARK Investment bought 708K shares of DraftKings on Tuesday

06:35 EDT Target sees Q2 comparable sales growth mid-to-high single digits - The company said, "For the second quarter of 2021, the Company expects mid-to-high single digit growth in comparable sales. The Company expects its second-quarter operating margin rate will be well above the second quarter 2019 rate of 7.2 percent, but likely not as high as last year's unprecedented 10.0 percent. The Company expects positive single-digit comparable sales growth in the last two quarters of the year, and expects its full-year operating margin rate will be well above the 2020 rate of 7.0 percent, with the potential to reach 8 percent or somewhat higher."

06:11 EDT Restaurant Brands' Burger King launches hand-breaded Ch'King chicken sandwich - The company stated, "The new hand-breaded Ch'King is finally here and available nationwide starting June 3. And ok, sure, we could have just named it a chicken sandwich, but that's just not how we do things at BK."

05:32 EDT Triumph Group, Boeing restructure and extend system components contract - Triumph Group (TGI) announced that it has secured multiple contract extensions with Boeing (BA), which will extend their collaboration on critical system components. The agreements extend Triumph's position as a supplier of hydraulic components across multiple Boeing programs. The three contract extensions, which were signed in the last month, secure Triumph's position as a systems provider for Boeing platforms. Under the contracts, Triumph's Actuation Products & Services operating company will manufacture the components at three of its U.S. based sites. Triumph's facility in Clemmons, North Carolina will begin work later this year to fulfill an extended long-term multi-year agreement for hydraulic actuation components for complex landing gear valves and thrust reverser cowl doors for the single aisle platforms. Triumph Actuation Products & Services has secured a multi-year contract extension to supply Boeing 787 Dreamliner landing gear components. The follow-on contract is for hydraulic locking actuators, transducers and control valve components on all 787 variants. Triumph has supplied these systems and components for the 787 aircraft since the program's inception and provides related repair and overhaul maintenance for other supplier partners and operators. The contract extension reaffirms Triumph's commitment to the 787 program and extends the company's strong working relationship with Boeing for years to come. Lastly, the Triumph site in Valencia, California has secured a multi-year contract extension to provide hydraulic accumulators, manifolds as well as steering and locking actuators for multiple legacy platforms.

05:23 EDT STMicroelectronics acquires Cartesiam, terms undisclosed - STMicroelectronics announced a transaction with Cartesiam to acquire its assets and to transfer and integrate its employees. Closing is subject to regulatory approvals.Cartesiam, based in Toulon, France, is a software company founded in 2016, which specializes in artificial intelligence, or AI, development tools enabling machine-learning and inferencing on Arm-based microcontrollers, which power billions of devices. Its team includes data scientists and embedded signal processing experts, with experience in delivering standard and custom solutions. Its patented solution, NanoEdge AI Studio, allows embedded systems designers without prior knowledge in AI to rapidly develop specialized libraries integrating machine-learning algorithms directly into a broad range of applications. Devices leveraging Cartesiam's technology are already in production around the world included inside connected devices, household appliances, and industrial machines. The terms of the transaction were not disclosed.